Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy controls: A preliminary study

Abstract

Four serum biomarkers reflecting altered MMP-mediated collagen turnover were able to differentiate ovarian and breast cancer patients from healthy controls.